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Abstract
A dengue-1 DNA vaccine containing sequences encoding premembrane and envelope proteins (DIME) was previously shown to elicit
virus neutralizing antibodies in rhesus and Aotus monkeys, and the primates were partially protected from viremia upon challenge. To
increase the neutralizing antibody levels and subsequent protection from virus challenge, four strategies were evaluated: (a) coimmunization
with a plasmid expressing Aotus GM-CSF gene; (b) coimmunization with a plasmid containing human immunostimulatory sequences (ISS);
(c) coimmunization with both the GM-CSF gene and ISS; and (d) delivery of vaccine using the needle-free Biojector system. Vaccination
with the mixed formulation containing DIME, GM-CSF gene, and ISS, by either needle injection or Biojector, led to neutralizing antibody
titers that were stable for up to 6 months after vaccination. Furthermore, 6 of 7 monkeys (85%), and 7 of 8 monkeys (87%) receiving this
formulation were completely protected from viremia when challenged 1 and 6 months after vaccination, respectively. This is a significant
improvement compared to our previous study in which one of three monkeys (33%) receiving just the DIME vaccine was completely
protected from viremia at 6 months after immunization.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Dengue is one of the most important arboviral diseases
of humans. An estimated 100 million dengue infections are
caused each year by four antigenically distinct serotypes of
dengue virus, resulting in widespread dengue fever (DF)
and at least 250,000 cases of dengue hemorrhagic fever
(DHF) (Halstead, 1988). These viruses are transmitted pri-
marily by the mosquito Aedes aegypti and are endemic
throughout the tropical and subtropical regions of the world.
A major expansion of dengue transmission has occurred
throughout the tropical Americas accompanied by a large
increase in the number of DHF cases. Despite the public
health importance of DF and DHF, vector control, which
has proven difficult and costly to sustain over time, is the
only available control measure (Gubler, 1994). Vaccines are
available for two related flaviviruses, yellow fever (YF)
virus and Japanese encephalitis (JE) virus (Barrett, 1997a,
1997b). However, decades of effort have not produced a
successful dengue virus vaccine. Live-attenuated dengue
viruses, while immunogenic, have been associated with
high reactogenicity and clinical complications (Edelman et
al., 1994; McKee et al., 1987). Inactivated dengue viruses
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have been less immunogenic (Schlesinger, 1977), and re-
combinant dengue proteins have failed to consistently pro-
tect nonhuman primates from homologous dengue virus
challenge (Deubel et al., 1988; Eckels et al., 1994).
DNA vaccines offer an alternative strategy for develop-
ing effective dengue virus vaccines. This approach, in
which plasmid DNA expressing an antigen of interest is
used as a vaccine, induces immune responses in animal
models against a number of different viruses, including
several flaviviruses (Colombage et al., 1998; Konishi et al.,
1998; Phillpotts et al., 1996; Schmaljohn et al., 1997). We
have previously shown that a dengue-2 DNA vaccine con-
taining the genes for premembrane (prM) and 92% of en-
velope (E) protein induced neutralizing antibody response
in mice (Kochel et al., 1997) and the vaccinated mice had a
higher survival rate following dengue-2 virus challenge
(Porter et al., 1998). When four different dengue-1 DNA
vaccine candidates expressing truncated or full-length E
with or without prM were compared, we observed that the
candidate expressing prM and full-length E produced virus-
like particles and elicited long-lasting neutralizing antibod-
ies in mice (Raviprakash et al., 2000a). We further showed
that this dengue-1 vaccine was immunogenic in nonhuman
primates and afforded complete to partial protection from
challenge (Kochel et al., 2000; Raviprakash et al., 2000b).
These primate trials provided proof of principle that a den-
gue DNA vaccine could elicit protective immune responses
in nonhuman primates. However, the studies also indicated
that it was necessary to find ways to improve neutralizing
antibody responses and protection from challenge. In this
study, we have evaluated three different strategies to
achieve this goal.
Results
Aotus monkeys were immunized as detailed in Table 1
and under Materials and methods. Three DNAs were used,
as follows: DIME (D) is plasmid VR1012 containing den-
gue-1 prM and E genes; VR1721 (G) is a plasmid express-
ing the Aotus GM-CSF gene; and pHis64 (I) is a plasmid
containing multiple copies of the human immunostimula-
tory sequences. The vaccines were delivered either by nee-
dle injection or by using the Biojector (BJ).
Antibody response
The antibody responses in each group of animals were
measured by single dilution (1:100) indirect ELISA, and the
results are shown in Fig 1. All of the vaccinated animals
except one in the DI group had seroconverted after the first
immunization (not shown). The antibody levels increased
somewhat after the second dose of vaccine and remained
stable until time of challenge (Fig. 1). All seven monkeys
that received a single subcutaneous dose of dengue-1 virus
(positive control) and none of the eight PBS injected (neg-
ative control) monkeys had dengue-specific antibody.
The ability of antidengue antibodies elicited by dengue-1
DNA vaccines to neutralize dengue-1 virus in vitro was
measured by plaque reduction neutralization test (PRNT).
Table 2 shows PRNT50 titers for individual animals at
months 3 (2 months after the first boost), 6 (1 month after
the second boost), and 11 (6 months after the second boost).
The third dose of vaccine given at month 5 had a strong
boosting effect on neutralizing antibody response, as re-
flected by neutralization titers in sera obtained at month 6.
For monkeys challenged at month 11, the neutralizing an-
tibody titers remained stable or only declined slightly be-
tween month 6 and 11. When mean titers (3 months) for
groups vaccinated with different formulations were com-
pared, only the virus-infected positive control group was
different from all other groups (P  0.0009). However at 6
months, significant differences were indicated only between
the positive control group compared to the PBS group (P 
0.001), the DI group (P  0.045), and the DGI group (P 
0.009), indicating that the neutralization titers for groups
vaccinated with D, DG, or DGI-BJ were not different from
that of the virus-infected positive control group. At 11
months, the titers for the positive control group differed
from the DGI group (P  0.026) but not the DGI-BJ group
(P  0.207).
Table 1
Study design
Group Vaccine, (0, 1, and 5 months) n No. challenged
Month 6 Month 11
1 PBS 8 4 4
2 D1ME (D) 4 4 —
3 D1ME  VR1721 (DG) 4 4 —
4 D1ME  pHis64 (DI) 4 4 —
5 D1ME  VR1721  pHis64 (DGI) 8 4 4
6 D1ME  VR1721  pHis64(BJ)a (DGI-BJ) 7 4 3
7 D1WP74b 7 3 4
a BJ denotes injection by Biojector.
b D1WP74 is dengue-1 virus Western Pacific 74 strain.
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Protection from live virus challenge
Animals were challenged with live dengue-1 virus at
month 6 (1 month after the third vaccine dose) and at month
11 (6 months after the third vaccine dose) to assess the
protective efficacy of vaccine-induced immune responses.
Four monkeys from groups vaccinated with D, DG, DI,
DGI, and three monkeys from group DGI-BJ were chal-
lenged at month 6 by subcutaneous injection of live den-
gue-1 virus, and serum samples from daily bleeds were
analyzed for the presence of infectious virus (viremia). Four
monkeys each from the PBS and D1WP74 groups were
included as controls. The PBS control animals developed
2–4 days of viremia (mean  3.25 days), whereas animals
previously infected with dengue-1 virus (D1WP74 group)
did not develop detectable viremia (Table 3). Compared to
PBS control animals, the duration of viremia was signifi-
cantly reduced in animals vaccinated with D (P  0.021),
DGI (P  0.039), DGI-BJ (P  0.011), and the previously
infected positive control group (P  0.006). Some break-
through viremia was observed in the presence of neutraliz-
ing antibody, for example, in animals 0835, WR323, and
WR339. Most significantly, six of the seven animals
(85.7%) vaccinated with DGI or DGI-BJ were completely
protected from viremia. The only viremic animal in this
group (WR399) failed to develop neutralizing antibody.
Another group of eight animals vaccinated with the same
formulation (four with DGI; four with DGI-BJ) were chal-
lenged 6 months after the last dose of vaccine. Seven of the
eight vaccinated animals (87.5%) were completely pro-
tected from viremia and one animal had a single day of
viremia (Table 4). The mean viremia days for the vaccinated
group (n  7) was 0.14 compared to 3.75 days for PBS
control group (n  4) (P  0.0009).
Discussion
This study has evaluated early and sustained antibody
responses to a dengue-1 DNA vaccine in Aotus monkeys,
administered with or without immune enhancing agents, by
needle injection and Biojector delivery. Significantly higher
neutralizing antibody titers were achieved by delivering
D1ME (D), D1ME plus VR1721 (DG), or a mixture of
D1ME, VR1721, and pHis64 via the Biojector (DGI-BJ). In
DGI-BJ-vaccinated animals which were followed for 6
Fig. 1. Animals were vaccinated at months 0, 1, and 5 (2). Sera from monthly bleeds were diluted 1:100 and assayed for dengue-specific antibody by ELISA
as described under Materials and methods. The mean ELISA OD and the standard deviation for each group are shown.
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months after immunization, the antibody levels did not
decline as observed in earlier trials of rhesus and Aotus
monkeys that were needle injected with vaccine DNA alone.
The antibody levels were completely protective with the
exception of one monkey that developed a single day of
detectable viremia. This is a significant improvement com-
pared to an earlier study in which only 33% protection was
achieved in Aotus monkeys vaccinated with D1ME alone
and challenged 6 months after third dose (Kochel et al.,
2000).
Most naked DNA vaccines have suffered from lower
than desired antibody responses. It is therefore important to
identify means by which to enhance antibody responses. We
have considered four such strategies for improving den-
gue-1 DNA vaccine. First, we chose to evaluate coimmu-
nization with pHis64 plasmid. This plasmid contains mul-
tiple copies of human-specific ISS. In a previous study, we
had observed that a dengue-2 DNA vaccine elicited better
antibody responses in mice when coinjected with pUC-19
plasmid DNA containing mouse-specific ISS (Porter et al.,
1998). Immunostimulatory sequences have been used as
adjuvants with both protein- and DNA-based vaccines. In
the case of gp120-depleted, whole killed HIV-1 vaccine, it
was shown that simultaneous injection of HIV-1 and oligo-
nucleotides containing ISS led to higher p24-specific anti-
body response, stronger lymphocyte proliferation and
-chemokine production (Moss et al., 2000, 2001). An
HIV-1 gp160 subunit vaccine induced a typical Th2 domi-
Table 2
50% virus neutralization titers in vaccinated Aotus monkeys
Vaccine Animal I.D. 3 months 6 months 11 months
PRNT50 Grp. Mean  SE PRNT50 Grp. Mean  SE PRNT50 Grp. Mean  SE
PBS 1251 0 0.0  0 0 0.0  0 0.0  0
2209 0 0
WR406 0 0
WR437 0 0
ICD2 0 0 0
1960 0 0 0
2164 0 0 0
WR423 0 0 0
D1ME (D) WR419 0 2.5  2 480 365.0  167
WR420 0 770
WR413 10 0
WR371 0 210
D1ME  1721 (DG) 0835 0 33.7  19 95 357.5  282
0610 65 1200
0999 0 0
WR409 70 135
D1ME  pHis64 (DI) WR323 0 3.7  3 180 156.2  74
WR454 0 0
WR339 0 95
WR417 15 350
D1ME  1721  pHis64
(DGI)
1985 24 21.1  5 415 161.8  42 78.7  24
0664 35 225
WR441 35 160
WR399 0 0
2339 20 150 150
2358 0 130 55
WR449 40 135 50
WR432 15 80 60
D1ME  1721  pHis64 (BJ)
(DGI-BJ)
WR445 0 60.0  18 80 307.8  71 332.5  117
T218 70 510
WR411 60 270
WR424 40 270 300
WR455 120 510 640
WR374 10 65 70
WR396 120 450 320
D1WP74 1958 90 402.8 89 240 859.2  253 753.3  309
WR416 580 1920
WR370 320 1535
T211 830 640
T261 320 1090 1280
0990 300 270 210
WR384 380 320 770
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Table 3
Viremia in Aotus monkeys vaccinated (0, 1, and 5 months) and challenged (6 months) with live dengue-1 virus
Vaccine Monkey I.D. Nt. ab.
titera
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Group
mean
Group
median
PBS 1 1251 0         3.25 3.50
2 2209 0        
3 WR406 0        
4 WR437 0        
D1ME (D) 5 WR419 480         0.50 0.00
6 WR420 770        
7 WR413 0        
8 WR371 210        
D1ME 
1721
(DG)
9 0835 95         1.00 0.00
10 610 1200        
11 0999 0        
12 WR409 135        
D1ME 
pHis64
(DI)
13 WR323 180         1.25 1.00
14 WR454 0        
15 WR339 95        
16 WR417 350        
D1ME 
1721 
pHis64
(DGI)
17 1985 415         0.75 0.00
18 0664 225        
19 WR441 160        
20 WR399 0        
D1ME 
1721 
pHis64
(BJ)
(DGI-BJ)
21 WR445 80         0.00 0.00
22 T218 510        
23 WR411 270        
D1WP74 24 1958 240         0.00 0.00
25 WR416 1920        
26 WR370 1535        
27 T211 640        
Note. Animals were challenged on day 0 by subcutaneous inoculation of live dengue-1 virus. Animals were bled daily thereafter and viremia was
determined as described under Materials and methods.  and  indicate presence or absence of virus, respectively.
a PRNT50 at the time of challenge.
Table 4
Viremia in Aotus monkeys vaccinated (0, 1, and 5 months) and challenged (11 months) with live dengue-1 virus
Vaccine Monkey I.D. Nt. ab. titera Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Group
mean
Group
median
PBS 1 ICD2 0         3.75 3.5
2 1960 0        
3 2164 0        
4 WR423 0        
D1ME 
1721 
pHis64
(DGI)
5 2339 150         0 0
6 2356 55        
7 WR449 50        
8 WR432 60        
D1ME 
1721 
pHis64
(BJ)
(DGI-BJ)
9 WR424 300         0.25 0
10 WR455 640        
11 WR374 70        
12 WR396 320        
D1WP74 13 T261 1280         0 0
14 0990 210        
15 WR384 770        
Note. Animals were challenged on day 0 by subcutaneous inoculation of live dengue-1 virus. Animals were bled daily thereafter and viremia was
determined as described under Materials and methods.  and  indicate presence or absence of virus, respectively.
a Fifty percent virus neutralization titers (PRNT50) at the time of challenge.
349K. Raviprakash et al. / Virology 315 (2003) 345–352
nated immune response in mice; however, when the mice
were boosted with vaccine plus ISS oligonucleotides, a
7-fold increase in the production of IgG2a antibodies and a
10-fold increase in the interferon- secreted by restimulated
splenic cells (Deml et al., 1999). In a study contrasting
immunostimulatory sequences (ISS) contained in plasmids
or oligonucleotides, it was shown that human monocyte-
derived dendritic cells are activated by ISS contained in
plasmid DNA but not by ISS in oligonucleotides (Schatten-
berg et al., 2000). All of these studies have utilized either
cell-culture models or mouse model systems and no data on
in vivo efficacy of ISS in higher animal systems are avail-
able. Although the differences were not statistically signif-
icant, this study suggests that coinjection of pHis64 plasmid
resulted in decreased neutralizing antibody levels. Groups
DI and DGI [(PRNT50)  156 and 161, respectively], both
had decreased antibody titers compared to vaccine DNA
alone (PRNT50  365).
Second, we evaluated coimmunization with VR1721, a
plasmid expressing Aotus GM-CSF gene. We have previ-
ously observed in mice that neutralizing antibody produced
by a dengue-2 DNA vaccine increased significantly when
the vaccine DNA was coinjected with plasmid expressing
murine GM-CSF gene. Several cytokine genes have been
used as genetic adjuvants for DNA vaccines. Among the
nine different cytokine genes tested with a rabies virus DNA
vaccine, GM-CSF consistently enhanced the immune re-
sponses (Xiang et al., 1997). Infiltration of CD11c imma-
ture dendritic cells at the site of GM-CSF DNA injection
has been postulated as a mechanism by which immune
responses are enhanced (Haddad et al., 2000). There has
been some concern regarding use of plasmids expressing
highly potent molecules such as GM-CSF. In a recent study
in mice and rabbits, repeated ID and IM injections of a
multivalent malaria DNA vaccine which included GM-CSF
plasmid was found to be safe and well tolerated without any
evidence of autioimmune pathology (Parker et al., 2001). In
this study, use of Aotus-specific GM-CSF gene did not
significantly affect the neutralizing antibody levels. In
groups vaccinated with vaccine DNA alone (D) or in com-
bination with GM-CSF plasmid (DG), three of four animals
seroconverted with mean PRNT50 titers of 365 and 476,
respectively.
Although the DGI formulation which contained both ISS
and GM-CSF gene in addition to vaccine DNA, did not
significantly increasing neutralizing antibody titers, it did
afford 100% protection to animals challenged 6 months
after vaccination. This is in contrast to 33% protection
observed in an earlier study in which animals were vacci-
nated with D1ME DNA alone and challenged 6 months
after (Kochel et al., 2000). When animals were vaccinated
with vaccine DNA alone, only three of the four animals
were protected when challenged 1 month after vaccination.
It is therefore possible that the immune enhancing agents
are enhancing protective immune responses other than neu-
tralizing antibody.
Our third strategy to improve dengue-1 DNA vaccine
utilized an alternate method of delivering the vaccine. De-
livery of agents via the needle-free Biojector results in a
better tissue distribution of the material. Use of Biojector
greatly increased the uptake of plasmid DNA expressing
human papilloma virus E7 gene (Manam et al., 2000). Ten-
to 50-fold higher antibody titers were reported for a malaria
DNA vaccine delivered by Biojector compared to that ob-
tained by needle injection (Aguiar et al., 2001). In a recent
clinical trial comparing hepatitis A virus vaccine delivered
by needle and Biojector, a higher proportion of people
vaccinated by Biojector seroconverted (Williams et al.,
2000). We immunized 15 Aotus monkeys with the mixed
formulation DGI, 8 by needle injection, and 7 by Biojector.
The needle-injected group had a mean PRNT50 titer of 161
at 6 months compared to 307 for the group injected by the
Biojector. In contrast to needle injection, the titers among
animals injected by the Biojector were more uniform and
consistent and did not decline from month 6 to month 11.
Although the titers in needle-injected animals were suffi-
cient to protect animals from challenge, we speculate that
the higher titers in Biojector-injected animals may afford
longer term protection from virus challenge. It will be in-
teresting to study some of these aspects in a human trial.
Materials and methods
Animals
Aotus monkeys (Aotus nancymae), of either sex, age 5 to
15 years, weighing between 0.85 and 1.1 kg, were housed at
the Naval Medical Research Center/Walter Reed Army In-
stitute of Research animal facility in Silver Spring, MD. The
monkeys were prescreened for the presence of dengue-
specific antibody by enzyme-linked immunosorbant assay
(ELISA) and PRNT. Only those animals that did not show
evidence of previous dengue exposure were included in the
study. Animals were excluded if the ELISA OD exceeded
two or more standard deviations at a 1:100 dilution of their
sera when tested against dengue-1 antigen compared to the
OD obtained with a negative control antigen, or if the sera
exhibited greater than 30% dengue-1 virus neutralization at
1:10 dilution in a standard PRNT.
DNA
The vaccine construct DIME containing dengue-1 prM
and full-length E genes cloned into vector pVR1012 (Vical
Inc., San Diego, CA) has been described previously (Ravi-
prakash et al., 2000a). VR1721 is a plasmid expressing the
Aotus GM-CSF gene. Plasmid pHis64 which contains mul-
tiple copies of human ISS was kindly provided by Dr.
Heather Davis, University of Ottawa, Canada. All DNA
were purified by alkaline lysis (Maniatis T, 1984) followed
by chromatography on a Sepharose S-1000 (Pharmacia)
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column (Horn et al., 1995). Endotoxin levels (30–50
EU/mg DNA) were determined by standard limulus amoe-
bocyte lysate assay.
Immunization
One microgram of vaccine DNA (D) was administered
either with or without 0.1 mg VR1721 (G) and/or 0.5 mg
pHis64 plasmid (I), as shown in the Study Design (Table 1),
and 0.4 ml of vaccine formulation (DNA in PBS) was
administered intradermally (id) at 4–6 sites in the chest
area. When Biojector was used to deliver vaccine, 4  100
l aliquots were delivered id in the thigh area. The vacci-
nations were repeated at months 1 and 5 after the initial
inoculation. The PBS control animals were injected id with
0.4 ml of PBS using a needle. The positive control
(D1WP74) group was inoculated (at time zero) subcutane-
ously in the upper left arm with 0.5 ml of DMEM containing
2  104 PFU of dengue-1 virus.
Antibody analyses
The monkeys were bled at monthly intervals, and their
sera were tested for dengue-1-specific antibody by ELISA
and/or PRNT. IgG antibody was detected by ELISA as
previously described (Ansari et al., 1993) except that poly-
ethylene glycol (PEG) precipitated dengue-1 virions were
used as the antigen, and a peroxidase-labeled antihuman
immunoglobulin was used as the conjugate. PRNT was
performed with vero cells as described (Russell et al., 1967),
using twofold serial dilutions of serum samples. A pool of
the sera of animals collected before they were primed was
used as the negative control for PRNT. PRNT50 titers were
determined by probit analysis. PRNT50 titers were consid-
ered zero if a 1:10 serum dilution caused less than 50%
reduction.
Virus challenge and viremia
Monkeys were challenged at either month 6 or month 11
(1 and 6 months after third dose, respectively; Table 1).
Each monkey was bled prior to challenge and then inocu-
lated subcutaneously in the upper left arm with 0.5 ml
DMEM containing 2  104 PFU of dengue-1 virus. The
virus used for challenge (dengue-1 Western Pacific 74) was
prepared from infected fetal Rhesus lung cells and was
kindly provided by Dr. K. Eckels, Walter Reed Army In-
stitute of Research (Silver Spring, MD). Monkeys were bled
daily for 10 days and again on days 21 and 28 after chal-
lenge. Sera were used to measure viremia and antibody
responses. Viremia was measured by inoculating 25-cm2
flasks of confluent Vero cells in duplicate with 0.2 ml of a
1:10 diluted serum sample. The inoculated cells were incu-
bated for 10 days at 37°C in a CO2 incubator. The cells were
then scraped off the flasks, washed with PBS, and spotted in
duplicate onto immunofluorescence slides. The slides were
processed for indirect immunofluorescent staining using
mouse monoclonal antibody 7E11 (specific for NS-1 pro-
tein) and FITC-conjugated anti-mouse immunoglobulin.
They were examined under a fluorescent microscope with
appropriate positive and negative controls.
Statistical analyses
Virus neutralization titers (mean titers for groups) and
the mean viremia days for each group were analyzed using
one-way ANOVA with Dunnett’s post-hoc test or Tukey
HSD test to determine whether there were significant dif-
ferences among groups in the virus neutralization titer and
viremia.
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